Short-term therapeutic effect of recombinant human endostatin combined with chemotherapy for advanced gastric cancer: a Meta-analysis
SU Hang,HU Bing,JI Chu-shu,HE Yi-fu,HAN Xing-hua,L(U) Ya-jing
DOI: https://doi.org/10.3781/j.issn.1000-7431.2015.33.735
2015-01-01
Tumor
Abstract:Objective: To evaluate the efficacy and safety of recombinant human endostatin (rh-endostatin) combined with chemotherapy for patients with advanced gastric cancer.Methods: A computer-based online search was performed through PubMed, Medline, Cochrane Library, Elsevier, Chinese BioMedical Literature Database, China National Knowledge Infrastructure (CNKI) and WanFang Database. According to the inclusion and exclusion criteria, the randomized controlled trials about short-term therapeutic effect of rh-endostatin combined with chemotherapy for advanced gastric cancer, which were published up to August 2014, were selected. Quality of the studies was assessed using modified Jadad scale. After data extraction, a Meta-analysis was performed by using RevMan 5.2 software. Relative risk (RR) and its 95% confidence interval (CI) were calculated. The Egger test was performed by using Stata 12.0 software.Results: Ten eligible randomized controlled trials were included in this Meta-analysis including 623 patients (308 in chemotherapy alone group, 315 in rh-endostatin combined with chemotherapy group). The results showed that there were significant improvements in complete response (CR) rate (9.21% vs 3.57%, RR = 2.24, 95% CI: 1.21-4.15, P = 0.01), partial response (PR) rate (46.35% vs 31.49%, RR = 1.47, 95% CI: 1.21-1.80, P = 0.000 1), overall response rate (ORR) (54.60% vs 39.29%, RR = 1.39, 95% CI: 1.17-1.65，P = 0.000 2) and clinical benefit rate (CBR) (81.27% vs 69.48%, RR = 1.17, 95% CI: 1.06-1.28, P = 0.001 0) in rh-endostatin combined with chemotherapy group, as compared with those of the chemotherapy along group. Meanwhile, there were no statistically significant differences in myelosuppression (61.96% vs 65.10%, RR = 0.95, 95% CI: 0.85-1.07, P = 0.42) and gastrointestinal reaction (58.03% vs 57.38%, RR = 1.01, 95% CI: 0.88-1.15, P = 0.93). However, the rate of cardiotoxicity was higher in rh-endostatin combined with chemotherapy group (12.36% vs 4.19%, RR = 2.82, 95% CI: 1.32-6.00, P = 0.007).Conclusion: This Meta-analysis indicates that in comparison with chemotherapy alone, rh-endostatin combined with chemotherapy has better therapeutic effect on advanced gastric cancer and the common adverse events do not increase. Therefore, rh-endostatin can be used as a routine drug for advanced gastric cancer. Meanwhile, it also increases the rate of cardiotoxicity, and more attention should be paid to this problem. DOI:10.3781/j.issn.1000-7431.2015.33.735